Fatty liver score and 15-year incidence of type 2 diabetes

Hepatology International

Volumn 7, Issue 2, 2013, Pages 610-621

  Kotronen, Anna ^a,b   Laaksonen, Maarit A ^a   Heliövaara, Markku ^a   Reunanen, Antti ^a   Tuomilehto, Jaakko ^b,c,d   Yki Järvinen, Hannele ^b   Peltonen, Markku ^a   Knekt, Paul ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Alcohol consumption; Attributable risk; Cohort studies; Fatty liver score; Liver fat; Liver function test; Type 2 diabetes; Vitamin D

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN D;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ALCOHOLIC FATTY LIVER; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FATTY LIVER SCORE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; VITAMIN BLOOD LEVEL;

EID: 84879841596     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-013-9430-7     Document Type: Article

References (47)

1. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-967
2. Everhart JE, Bambha KM. Fatty liver: think globally. Hepatology. 2010;51:1491-1493
3. Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 2008;34:634-637
4. Boppidi H, Daram SR. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgrad Med. 2008;120:E01-E07
5. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27-38
6. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51:1947-1953
7. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231
8. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212-1218
9. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854
10. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/non- alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol. 2004;18:1089-1104
11. Kotronen A, Yki-Järvinen H, Männistö S, Saarikoski L, Korpi-Hyovälti E, Oksa H, Saltevo J, Saaristo T, Sundvall J, Tuomilehto J, Peltonen M. Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health. 2010;10:237
12. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008;135:1935-1944. 1944.e1
13. Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomilehto J. gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab. 2004;89:5410-5414
14. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359:2220-2232
15. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005;28:2913-2918
16. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889-1895
17. Sattar N, McConnachie A, Ford I, Gaw A, Cleland SJ, Forouhi NG, McFarlane P, Shepherd J, Cobbe S, Packard C. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes. 2007;56:984-991
18. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007;92:3490-3497
19. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395
20. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander M, Yki-Järvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865-872
21. Knekt P, Laaksonen M, Mattila C, Härkänen T, Marniemi J, Heliövaara M, Rissanen H, Montonen J, Reunanen A. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology. 2008;19:666-671
22. Laaksonen MA, Knekt P, Rissanen H, Härkänen T, Virtala E, Marniemi J, Aromaa A, Heliövaara M, Reunanen A. The relative importance of modifiable potential risk factors of type 2 diabetes: a meta-analysis of two cohorts. Eur J Epidemiol. 2010;25:115-124
23. Mattila C, Knekt P, Männistö S, Rissanen H, Laaksonen MA, Montonen J, Reunanen A. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care. 2007;30:2569-2570
24. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92:2017-2029
25. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92:4-8
26. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, Strasser M, Datz C, Weiss G. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr. 2008;87:1374-1383
27. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men - role of the metabolic syndrome. Thromb Haemost. 1996;76:69-73
28. Aromaa A, Heliövaara M, Impivaara O, Knekt P, Maatela J. The execution of the Mini-Finland Health Survey. Part 1: Aims, Methods, and Study Population. Helsinki and Turku: Publications of the Social Insurance Institution ML:88; 1989
29. Kostner GM. Letter: enzymatic determination of cholesterol in high-density lipoprotein fractions prepared by polyanion precipitation. Clin Chem. 1976;22:695
30. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202-1219
31. Reunanen A, Kangas T, Martikainen J, Klaukka T. Nationwide survey of comorbidity, use, and costs of all medications in Finnish diabetic individuals. Diabetes Care. 2000;23:1265-1271
32. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Geneva: WHO; 1985
33. Heliövaara M, Reunanen A, Aromaa A, Knekt P, Aho K, Suhonen O. Validity of hospital discharge data in a prospective epidemiological study on stroke and myocardial infarction. Acta Med Scand. 1984;216:309-315
34. Reunanen A, Aromaa A, Pyörälä K, Punsar S, Maatela J, Knekt P. The Social Insurance Institution's coronary heart disease study. Baseline data and 5-year mortality experience. Acta Med Scand Suppl. 1983;673:1-120
35. Friedman M. Piecewise constant hazards models for survival data with covariates. Ann Stat. 1982;10:101-113
36. Chiang PH, Chang TY, Chen JD. Synergistic effect of fatty liver and smoking on metabolic syndrome. World J Gastroenterol. 2009;15:5334-5339
37. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-1850
38. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, Blendis L, Halpern Z, Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology. 2008;48:1791-1798
39. Shah VH. Alcoholic liver disease: the buzz may be gone, but the hangover remains. Hepatology. 2010;51:1483-1484
40. Wannamethee SG, Camargo CA Jr, Manson JE, Willett WC, Rimm EB. Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger women. Arch Intern Med. 2003;163:1329-1336
41. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, Arcaro G. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17:517-524
42. Jääskeläinen T, Knekt P, Marniemi J, Sares-Jäske L, Männistö S, Heliövaara M, Järvinen R. Vitamin D status is associated with sociodemographic factors, lifestyle and metabolic health. Eur J Nutr. 2012;52:513-525
43. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;2:33
44. Bajaj S, Nigam P, Luthra A, Pandey RM, Kondal D, Bhatt SP, Wasir JS, Misra A. A case control study on insulin resistance, metabolic co-variates & prediction score in non alcoholic fatty liver disease. Indian J Med Res. 2009;129:285-292
45. Norris RL, Thomas MJ, Craswell PW. Assessment of a two-step high-performance liquid chromatographic assay using dual-wavelength ultraviolet monitoring for 25-hydroxyergocalciferol and 25-hydroxycholecalciferol in human serum or plasma. J Chromatogr. 1986;381:53-61
46. Stamp TC, Round JM. Seasonal changes in human plasma levels of 25-hydroxyvitamin D. Nature. 1974;247:563-565
47. Knekt P, Marniemi J, Teppo L, Heliövaara M, Aromaa A. Is low selenium status a risk factor for lung cancer? Am J Epidemiol. 1998;148:975-982